HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever names CFO

This article was originally published in The Rose Sheet

Executive Summary

Jean-Marc Huet moves to Unilever as chief financial officer from the same post at Bristol-Myers Squibb, according to a Dec. 16 release. Effective Jan. 1, Huet will succeed James A. Lawrence, who retired to pursue new opportunities. Huet says he "is looking forward enormously to the challenge" of the job and the "ambitious vision" for the company that has been set out by Unilever CEO Paul Polman. Unilever announced Dec. 12 it is suspending purchases from a major supplier due to allegations of environmental abuses (see story, 1Unilever Halts Palm Oil Purchases From Alleged Forest Destroyer).

You may also be interested in...



Unilever Halts Palm Oil Purchases From Alleged Forest Destroyer

Unilever - the world's largest buyer of palm oil -has suspended its purchases from PT SMART due to allegations that the Indonesian supplier illegally destroyed areas of forest to harvest palm oil

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief. 

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel